
[ad_1]
March 6, 2024 — Bodyport Inc., a heart failure-focused biomarker-based predictive therapy company, announces its FDA-cleared non-invasive biomarker-based remote heart failure monitoring technology has been detected twice We have announced the latest presentation data. Reduces the number of heart failure events compared to weight-based standard care. According to a statement from the company regarding the findings, this was demonstrated using the same monitoring routine that patients already do when weighing themselves daily, while minimizing false alarms to care teams. The company says it has reduced overall alert occurrences by about 40 percent.
Data from a preliminary analysis of Bodyport’s SCALE-HF 1 study was presented today at the Cardiovascular Research Foundation’s (CRF) Third Annual Technology and Heart Failure Therapeutics (THT), held in October 2016. On the last day of the conference, the latest research results were presented in a session.boston, massachusetts
The Bodyport Heart Health solution captures hemodynamic signals through the FDA-cleared Bodyport Cardiac Scale to deliver patient-optimized interventions.
“These findings represent a significant improvement over the standard of care, which requires patients to step on a scale every day to detect worsening heart failure,” said Marat, an advanced heart failure specialist and MHS professor who submitted the data. Dr. Hudim said. Cardiologist at Duke University Medical Center. “While this biomarker-based technology also takes advantage of the familiar routine for patients of stepping on the scale, the scale’s sensors and algorithms double the number of predicted heart failure events and lead to serious complications. This has greatly increased the usefulness of remote monitoring to avoid “potentially leading to hospitalization.” ”
“This is welcome news for patient care teams, as fewer false alarms and improved prediction rates lead to more effective and efficient care,” said Dr. said Corey Centen, Chief Technology Officer. “Furthermore, the use of cardiac scales and congestion indices is a seamless transition for clinicians and patients because they enhance, rather than replace, existing pathways built around weight monitoring.” Lower alert rates result in higher volumes Overburdened with notifications and data, care teams can streamline their workflows by spending less time responding to false alerts. ”
Learn more about heart health solutions research
SCALE-HF 1, “Using Cardiac Scales to Predict Heart Failure Events: Design of SCALE-HF 1,” was a prospective study of 329 enrolled participants at 8 institutions with 238 patient-years of follow-up. It was an observational study. Participants were measured standing barefoot on the Bodyport Cardiac Scale at home for approximately 20 seconds each day. The Bodyport Cardiac Scale is a non-invasive device with the familiar shape of a scale. The data collected includes congestion-related biomarkers from FDA-cleared devices, which are used as input to the company’s algorithm, known as the Congestion Index. This latest study shows that the congestion index accurately predicts heart failure events (HFE). A heart failure event (HFE) was defined in this study as unplanned intravenous diuretic administration or hospitalization with a primary diagnosis of heart failure.
Across the study, the congestion index accurately predicted 48 of 69 heart failure events (70%), with significantly higher sensitivity (p<0.01) than the standard of care using scales. With standard weight rules, defined as weight gain of more than 3 pounds in a day or 5 pounds in a week, HFE was detected in only 24 of his 69 cases (35%), half the congestion index.
In addition to improved sensitivity in detecting heart failure events, the Congestion Index does so at a lower alert rate, generating only 4.18 alerts per patient-year compared to standard care. There were 2.58 items.
Of the 329 patients enrolled in the study, the mean age was 64 years (+/-14 years), 43 percent were female, and 32 percent were black. Additionally, 56 percent of patients had a left ventricular ejection fraction (LVEF) of 40% or less (also known as “decreased EF”), while 36 percent of patients had a left ventricular ejection fraction (LVEF) of 40% or less, or EF Save”. The congestion index is applicable to a wide range of heart failure patients.
Bodyport Inc., based in San Francisco, California, is a biomarker-based predictive therapeutics company that addresses complex chronic diseases by incorporating sophisticated biomarker platforms into simple, easy-to-use devices. The company has offered to focus on heart failure patients and non-invasive assessment of heart function and fluid status in one step at home, aiming to maintain the health of cardiorenal disease patients and discharge them from hospital.
More information: www.bodyport.com
[ad_2]
Source link